Video

Dr. Mirhadi on Patient Populations of Lung Cancer Optimal for Radiation

Amin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.

Amin J. Mirhadi, MD, associate professor of radiation oncology, Cedars-Sinai Medical Center, discusses patient populations of lung cancer who should be treated with radiation therapy.

The most common treatment option for patients with stage I lung cancer is radiation therapy, which is meant for patients who are either inoperable or forgo surgery. Radiation for patients with stage I lung cancer is an effective treatment, with about an 85% to 95% success rate in terms of eradicating the tumor, says Mirhadi.

Radiation therapy is also for patients with stage III lung cancer who have, essentially, the same primary tumor as those with stage I lung cancer but the tumor has spread to the mediastinal lymph nodes. For that patient population, radiation can be given in a standard-fractionated approach to treat all areas of active disease that are noted on the patient’s imaging. Those are the most common scenarios that radiation oncologists are involved with in the patient’s therapy, concludes Mirhadi.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center